When a pregnant person has Rh-negative blood and their baby inherits Rh-positive blood from the father, the mother's immune system may produce antibodies that attack the baby's red blood cells. This condition, known as hemolytic disease of the fetus and newborn (HDFN), can cause severe anemia, jaundice, or stillbirth if left untreated. Preventive treatment with Rh immune globulin (RhoGAM) is standard care.
Rh-negative blood occurs in about 15% of people of European descent and less than 5% of those of African or Asian ancestry. The Rh factor is a protein on red blood cells. If absent, the blood type is Rh-negative. During pregnancy, Rh incompatibility arises when an Rh-negative mother carries an Rh-positive fetus. The risk increases with fetal-maternal bleeding during delivery, amniocentesis, or trauma.
The American College of Obstetricians and Gynecologists (ACOG) recommends administering Rh immune globulin at 28 weeks gestation and again within 72 hours after birth if the baby is Rh-positive. This prevents maternal sensitization-the process where the immune system forms anti-D antibodies. Without intervention, subsequent pregnancies face higher HDFN risk. A single dose of RhoGAM suppresses antibody formation in 99% of cases, according to the National Institutes of Health (NIH).
Rh incompatibility begins when fetal red blood cells cross into the maternal bloodstream. This typically happens during delivery, but can occur earlier during amniocentesis, chorionic villus sampling, or abdominal trauma. Once exposed, the mother's immune system may produce IgG anti-D antibodies. These antibodies can cross the placenta in future pregnancies and destroy the fetus's red blood cells.
First pregnancies rarely result in HDFN because the mother's immune response develops too late. However, in subsequent pregnancies, the immune system responds faster and stronger. By the time the second Rh-positive baby is born, the mother may have high levels of anti-D antibodies, increasing the risk of severe anemia, hydrops fetalis (fluid accumulation), or death in utero.
A 2021 study published in the journal Obstetrics & Gynecology found that among 1,200 Rh-negative women who received RhoGAM prophylaxis, only 0.3% developed sensitization. In contrast, among 1,000 unsupervised Rh-negative women, 12% became sensitized. This confirms that RhoGAM reduces sensitization risk by over 97%.
Screening begins early in pregnancy. All pregnant individuals receive blood typing and Rh testing at the first prenatal visit. If the mother is Rh-negative, her partner's blood type is assessed. If the father is Rh-positive, the fetus may inherit Rh-positive status, necessitating monitoring.
Antibody screening is performed at 28 weeks and again at 36 weeks. If anti-D antibodies are detected, fetal surveillance intensifies. Ultrasound Doppler studies measure middle cerebral artery peak systolic velocity (MCA-PSV) to assess fetal anemia. Elevated MCA-PSV indicates significant anemia requiring intrauterine transfusion.
For example, a woman with Rh-negative blood and an Rh-positive partner had a normal MCA-PSV at 32 weeks. At 36 weeks, MCA-PSV rose to 1.5 multiples of the median (MoM), indicating moderate anemia. She received a second dose of RhoGAM and underwent weekly monitoring. The baby was delivered at 38 weeks via cesarean due to declining fetal heart rate. Postnatal blood tests confirmed mild HDFN, treated with phototherapy.
Many assume Rh-negative blood is inherently dangerous during pregnancy. This is false. With proper care, outcomes are excellent. Rh-negative mothers who receive timely RhoGAM have near-zero risk of HDFN in future pregnancies.
Another misconception is that Rh incompatibility affects fertility. It does not. The condition only impacts pregnancy outcomes when untreated. Some believe RhoGAM causes autism or autoimmune disorders. No credible evidence supports this claim. The FDA has reviewed over 50 million doses since 1968 with no causal link to developmental disorders.
Rh-negative blood is not linked to higher rates of miscarriage or preterm labor. These outcomes stem from other factors such as hypertension, diabetes, or infections. A 2020 cohort study in BJOG: An International Journal of Obstetrics & Gynaecology found no difference in preterm birth rates between Rh-negative and Rh-positive women when both received standard prenatal care.
| Feature | Rh-Negative Blood | Rh-Positive Blood |
|---|---|---|
| Prevalence in U.S. | 15% | 85% |
| Protein on RBCs | Absent | Present |
| Risk of HDFN | High if untreated | N/A |
| Need for RhoGAM | Yes, if partner is Rh-positive | No |
Any vaginal bleeding during pregnancy warrants evaluation. Even minor spotting can trigger fetal-maternal hemorrhage. If you're Rh-negative and experience bleeding, contact your provider immediately. Delaying RhoGAM beyond 72 hours reduces protection efficacy.
After delivery, confirm the baby's Rh status. If positive, the mother must receive RhoGAM within 72 hours. Failure to do so increases the risk of sensitization. Routine postpartum administration prevents complications in future pregnancies.
Although Rh-negative blood is relatively rare, it is manageable. The combination of routine screening, timely RhoGAM administration, and fetal monitoring makes adverse outcomes extremely uncommon. Genetic inheritance explains the low frequency-it requires two recessive alleles, which are infrequent in most populations.
With current medical protocols, Rh negative blood while pregnant poses no significant threat to mother or child. Early diagnosis and adherence to preventive care ensure healthy births and safe future pregnancies.